Skip to main content
Equibles
LGND logo

LGND · Ligand Pharmaceuticals Inc · Metrics

Track LGND — free

Use LGND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LGND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$314.78 +8.38 (+2.73%) At close · Oct 21
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$6.28B
Shares
19.94M
Volume · Oct 21 222.76K Avg daily vol (3M) 245.45K

LGND metrics

102 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$314.78
Market cap
$6.28B

Price action

20 metrics
Price change (1W)
+6.7%
Price change (30D)
+5.5%
Price change (3M)
+3.5%
Price change (6M)
+38.7%
Price change (YTD)
+66.5%
Price change (1Y)
+68.6%
Trailing year
Price change (5Y)
—
52-week high
$322.61
52-week low
$181.65
Change from 52-week high
-2.4%
Change from 52-week low
+73.3%
Annualized volatility
37.0%
Annualized volatility (3M)
28.7%
Beta
0.8
RSI (14D)
61.2
Price vs SMA 50
+7.3%
Price vs SMA 200
+26.6%
Avg volume (3M)
245,454
Relative volume
0.9
Average dollar volume
$72.37M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
19.94M

Valuation

12 metrics
P / E (TTM)
32.6
Trailing earnings · reciprocal yield 3.1%
PEG ratio
0.0
EV / revenue
20.2×
reciprocal yield 4.9%
EV / EBITDA
46.0×
reciprocal yield 2.2%
EV / EBIT
62.0×
reciprocal yield 1.6%
P / sales
21.0×
reciprocal yield 4.8%
P / book
6.3
reciprocal yield 15.8%
FCF yield
2.2%
TTM · current market cap
Buyback yield
1.2%
P / FCF
46.5
reciprocal yield 2.2%
P / operating cash flow
46.4
reciprocal yield 2.2%
Earnings yield
3.2%

Historical valuation

8 metrics
P / E historical average (3Y)
43.7×
reciprocal yield 2.3%
P / E historical average (5Y)
45.9×
reciprocal yield 2.2%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.2%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
32.6%
Trailing 12 months
Net margin
67.9%
Gross profit (TTM)
$140.50M
Operating profit (TTM)
$94.73M
Net income (TTM)
$197.22M
Trailing 12 months
Diluted EPS (TTM)
$9.65
FCF margin
45.2%
Effective tax rate
17.1%

Per share

11 metrics
Revenue per diluted share (TTM)
$13.90
Gross profit per diluted share (TTM)
$6.86
Operating profit per diluted share (TTM)
$4.58
EBITDA per diluted share (TTM)
$6.15
Net income per diluted share (TTM)
$9.33
Operating cash flow per diluted share (TTM)
$6.33
Free cash flow per diluted share (TTM)
$6.31
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$1.96
Stock compensation per diluted share (TTM)
$2.54
Book value per share
$51.44

Growth

11 metrics
Revenue growth YoY
+33.7%
Year over year
Net income growth YoY
+900.8%
Revenue (TTM)
$290.54M
Trailing 12 months
EPS growth YoY
+825.0%
Shares change YoY
+9.6%
Year over year · more shares
Revenue CAGR (3Y)
+11.0%
Revenue CAGR (5Y)
+10.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
-25.8%
FCF CAGR (5Y)
-0.5%

Quality

14 metrics
Return on equity
20.4%
Return on assets
9.0%
Debt / equity
1.2
Current ratio
31.2
EBITDA (TTM)
$127.65M
Free cash flow (TTM)
$131.44M
Quick ratio
31.0
Interest coverage
15.3
Net debt / EBITDA
-1.8
Return on invested capital
10.7%
Trailing 12 months
Net cash
$231.16M
Latest balance sheet
Cash & equivalents
$1.01B
Total assets
$2.19B
Total debt
$1.13B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$131.71M
Capital expenditures (TTM)
$278,000
R&D (TTM)
$41.35M
SG&A (TTM)
—
Stock compensation (TTM)
$53.27M
R&D / revenue
14.2%
Stock compensation / revenue
18.3%

Ownership (13F)

9 metrics
13F filers
423
13F filer change QoQ
+62
Institutional ownership
114.1%
Conviction holders (share of 13F filers)
3.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+10.7%
Holder tenure
14.7
Price vs estimated holder cost
+110.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
35.8%

Short interest

3 metrics
Short interest
13.4%
Latest settlement · 8.7 days to cover
Days to cover
8.7d
Short-squeeze score
76 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$16.07M
Insider-sentiment score
24 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 886163 CUSIP 53220K504 13F (30d) 68 filings 67 filers Visit website Investor relations